Neurocrine Biosciences - NBIX Stock Forecast, Price & News

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Wall Street Analyst Weigh In

NBIX has been the topic of several research analyst reports. Robert W. Baird increased their target price on Neurocrine Biosciences from $117.00 to $125.00 in a report on Friday, August 5th. Morgan Stanley raised their price target on Neurocrine Biosciences from $100.00 to $102.00 and gave the company an "equal weight" rating in a report on Friday, July 15th. Barclays raised their price target on Neurocrine Biosciences from $110.00 to $113.00 and gave the company an "overweight" rating in a report on Friday, August 5th. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Monday, August 8th. Finally, Wedbush reiterated an "outperform" rating on shares of Neurocrine Biosciences in a report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $113.60.

Neurocrine Biosciences Stock Up 1.7 %

Shares of Neurocrine Biosciences stock opened at $107.39 on Tuesday. The business's 50 day simple moving average is $96.83 and its 200 day simple moving average is $92.23. Neurocrine Biosciences has a 52-week low of $71.88 and a 52-week high of $109.26. The firm has a market cap of $10.27 billion, a PE ratio of 976.36 and a beta of 0.59. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.47 and a current ratio of 3.57.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 754 shares of the firm's stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $100.00, for a total value of $75,400.00. Following the completion of the transaction, the insider now directly owns 16,918 shares in the company, valued at $1,691,800. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.40% of the company's stock.